Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Ordinary Shares, Nominal value 0.12 per share
-
Shares outstanding
-
112M
-
Number of holders
-
35
-
Total 13F shares, excl. options
-
50.2M
-
Shares change
-
+1.34M
-
Total reported value, excl. options
-
$464M
-
Value change
-
+$5.44M
-
Number of buys
-
18
-
Number of sells
-
-9
-
Price
-
$9.25
Significant Holders of NewAmsterdam Pharma Co N.V. - Ordinary Shares, Nominal value 0.12 per share (NAMS) as of Q3 2023
39 filings reported holding NAMS - NewAmsterdam Pharma Co N.V. - Ordinary Shares, Nominal value 0.12 per share as of Q3 2023.
NewAmsterdam Pharma Co N.V. - Ordinary Shares, Nominal value 0.12 per share (NAMS) has 35 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 50.2M shares
of 112M outstanding shares and own 44.7% of the company stock.
Largest 10 shareholders include Frazier Life Sciences Management, L.P. (12.1M shares), Bain Capital Life Sciences Investors, LLC (10.5M shares), RA CAPITAL MANAGEMENT, L.P. (9M shares), VIKING GLOBAL INVESTORS LP (8.02M shares), Medicxi Ventures Management (Jersey) Ltd (2.87M shares), BVF INC/IL (1.52M shares), GMT CAPITAL CORP (1.38M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.2M shares), MILLENNIUM MANAGEMENT LLC (1.04M shares), and Eversept Partners, LP (661K shares).
This table shows the top 35 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.